# Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

> **NCT01154387** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tolera Therapeutics, Inc** · enrollment: 85 (estimated)

## Conditions studied

- End Stage Renal Disease
- Renal Transplant

## Interventions

- **DRUG:** Anti-Thymocyte Globulin
- **DRUG:** TOL101
- **DRUG:** TOL101
- **DRUG:** Steroids
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil (MMF)

## Key facts

- **NCT ID:** NCT01154387
- **Lead sponsor:** Tolera Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2013-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154387, "Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01154387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*